LARVOL Onco Data Podcast with Opus Strategy | E.31
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
LARVOL Onco Data Podcast with Opus Strategy | E.31
-
Lu par :
-
De :
À propos de ce contenu audio
Post-ESMO - European Society for Medical Oncology Insights with Christian Hayden from Opus Strategy, LLC and Mark Gramling In this episode of the LARVOL Onco Data Podcast, Mark Gramling teams up with Christian Hayden from Opus Strategy to deliver rapid-fire insights following the ESMO conference. They dive into the outcomes of the Tevosa trial, discussing how, despite some disappointing results, the trial addressed critical research questions that will guide future oncological treatments. Christian and Mark also explore the role of clinical research in shaping oncology care and how findings like these influence oncologists’ decisions worldwide. The conversation balances analysis with a lighthearted wrap-up, reflecting on the importance of transparency in clinical trials. Tune in for takeaways from ESMO and beyond, and catch up on how Opus Strategy and LARVOL are navigating the evolving oncology landscape!
#ONCOLOGY #LARVOL #ESMO
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
